The diagnostics test company Cepheid, and its parent corporation Danaher, make the lifesaving GeneXpert test technology, which is used in MSF medical programmes and beyond, to test people for many different diseases, including TB, HIV, and hepatitis. However, these tests are expensive in low- and middle-income countries. MSF and others have been calling on Danaher and Cepheid to lower the prices of these tests, so many more people can be diagnosed quickly and receive timely treatment.
The following national treatment programmes, as well as other groups, have sent these open letters to Danaher and Cepheid, calling for access to more affordable GeneXpert tests.
- Americas TB Coalition, 8 April 2024
- Belarus: Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Ministry of Health, 2 April 2024
- Ghana: National AIDS/STI Control Programme, 22 April 2024
- Poland: Institute of Tuberculosis and Lung Diseases, 26 April 2024
- Sierra Leone: National Leprosy and Tuberculosis Control Programme, 2 April 2024
